Middle Initial Omitted From Author Name in the Article by Felson et al (Arthritis Rheumatol, February 2017)

G, J eru I. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant 2012;27:1898–901. 28. Alpay N, Sumnu A, Calışkan Y, Yazıcı H, T€ urkmen A, G€ ul A. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int 2012;32:3277–9. 29. Eroglu FK, Beşbaş N, Topaloglu R, Ozen S. Treatment of colchicine-resistant familial Mediterranean fever in children and adolescents. Rheumatol Int 2015;35:1733–7. 30. Başaran € O, Uncu N, Çelikel BA, Taktak A, G€ ur G, Cakar N. Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol 2015; 25:621–4. 31. Cetin P, Sari I, Sozeri B, Cam O, Birlik M, Akkoc N. Efficacy of interleukin-1 targeting treatments in patients with familial Mediterranean fever. Inflammation 2015;38:27–31. 32. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997;40:1879–85. 33. Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A, et al. FMF50: a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis 2014;73:897–901. 34. Kaiser C, Knight A, Nordstr€ om D, Pettersson T, Fransson J, Florin-Robertsson E, et al. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int 2012;32:295–9. 35. Ombrello AK, Barron KS, Hoffmann PM, Jones A, Stone D, Kastner DL. An escalating dose of anakinra in patients with autoinflammatory disease is a safe and reasonable therapeutic option [abstract]. Arthritis Rheum 2013;65 Suppl:S509. 36. € Ozçakar ZB, € Ozdel S, Yılmaz S, Kurt-Ş€ uk€ ur ED, Ekim M, Yalçınkaya F. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol 2016;35:441–6. 37. Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 2012;157:533–41. 38. Zemer D, Livneh A, Danon YL, Pras M, Sohar E, et al. Longterm colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 1991;34:973–7. 39. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986;314:1001–5. 40. Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 1991;70:246– 56. 41. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361–71. 42. Lidar M, Yonath H, Shechter N, Sikron F, Sadetzki S, Langevitz P, et al. Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev 2012;12:72–6. 43. Buskila D, Zaks N, Neumann L, Livneh A, Greenberg S, Pras M, et al. Quality of life of patients with familial Mediterranean fever. Clin Exp Rheumatol 1997;15:355–60. 44. Deger SM, Ozturk MA, Demirag MD, Aslan S, Goker B, Haznedaroglu S, et al. Health-related quality of life and its associations with mood condition in familial Mediterranean fever patients. Rheumatol Int 2011;31:623–8. 45. Sahin S, Yalcin I, Senel S, Ataseven H, Uslu A, Yildirim O, et al. Assessment life quality of familial Mediterranean fever patients by short form-36 and its relationship with disease parameters. Eur Rev Med Pharmacol Sci 2013;17:958–63. 46. Ozen F, Silan C, Uludag A, Candan F, Silan F, Ozdemir S, et al. Association between ABCB1 (MDR1) gene 3435 C.T polymorphism and colchicine unresponsiveness of FMF patients. Ren Fail 2011;33:899–903. 47. Tufan A, Babaoglu MO, Akdogan A, Yasar U, Calguneri M, Kalyoncu U, et al. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol 2007; 34:1540–4. 48. Bezalel Y, Gershoni-Baruch R, Dagan E, Lidar M, Livneh A. The 3435T polymorphism in the ABCB1 gene and colchicine unresponsiveness in familial Mediterranean fever [letter]. Clin Exp Rheumatol 2009;27 Suppl 53:S103–4. 49. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11:633–52. 50. Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 2013;25:469–84.